Allstate Corp Takes Position in Cencora, Inc. (NYSE:COR)

Allstate Corp purchased a new position in shares of Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,349 shares of the company’s stock, valued at approximately $1,202,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JFS Wealth Advisors LLC lifted its stake in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after purchasing an additional 46 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in Cencora during the fourth quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC boosted its stake in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after buying an additional 69 shares during the last quarter. Kentucky Trust Co acquired a new position in Cencora during the fourth quarter worth $33,000. Finally, WASHINGTON TRUST Co grew its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after buying an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the sale, the chief executive officer now owns 51,070 shares of the company’s stock, valued at $13,022,850. This trade represents a 8.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock valued at $8,034,778 in the last 90 days. Company insiders own 10.80% of the company’s stock.

Cencora Trading Up 0.4 %

COR opened at $275.16 on Monday. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $275.57. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business has a fifty day simple moving average of $253.81 and a 200-day simple moving average of $241.24. The firm has a market cap of $53.36 billion, a P/E ratio of 39.14, a P/E/G ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.80%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on COR shares. Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Wells Fargo & Company increased their price objective on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. Finally, JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.